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Oral administration of Lu 35-138, a low aqueous soluble compound, was investigated in three different
formulations containing sulfobutylether b-cyclodextrin (SBE7bCD) in fasted beagle dogs. The evaluated
formulations was (i) a SBE7bCD solution, (ii) a spray dried solution ﬁlled into hard gelatine capsules,
and (iii) a direct compressible tablet containing SBE7bCD. The three formulations did not lead any
signiﬁcant differences in the obtained AUCs, though a trend was observed for the highest absorption
when Lu 35-138 was dosed in the cyclodextrin solution. These results demonstrate that a solid
formulation with a relative low content of cyclodextrins can be used to increase the bioavailability of a
low water soluble compound to a relative high level when compared to a cyclodextrin solution.
& 2011 Elsevier B.V. All rights reserved.1. Introduction
The number of poorly water-soluble drug candidates, encoun-
tered in drug discovery and development, causes increasing
problems with poor and variable bioavailability. In the early
phases of drug discovery and drug development a potential way
of overcoming these biopharmaceutical problems is by the use of
cyclodextrins (CDs) [7]. CDs are cyclic oligosaccharides consisting
of several glycopyranose units with an outer hydrophilic surface
and an inner hydrophobic cavity. The capability of CDs to form
inclusion complexes with drug compounds, thereby improving
their physico chemical properties, such as solubility and stability,
has been studied extensively (review by e.g. [1,2,13]). A number
of chemically modiﬁed CDs have been prepared to improve the
inclusion capacity and the physico chemical properties of the
native CDs. Of the CD derivatives, 2-hydroxypropyl-b-cyclodex-
trin (HPbCD) and sulfobutylether b-cyclodextrin (SBE7bCD) are
the most frequently used within the pharmaceutical ﬁeld on
account of their fast dissolution rate, high solubility in water
and low toxicity [4,10,12].
From a drug development point of view, the relative large
molecular weight of HPbCD and SBE7bCD can be a limitation forll rights reserved.
þ45 3643 8272.
Bagsværd 2880, Denmark.their use in solid oral dosage forms. The drug:CD mole ratio
required for the inclusion complexes are frequently above one to
one. For this reason a signiﬁcant amount of CDs needs to be
incorporated into the formulation, meaning that solid formula-
tions as tablets or capsules containing CD would become relatively
large and thereby difﬁcult to swallow for the patient and expen-
sive to produce for the company. Native bCDs and bCD derivatives
are hardly absorbed from the gastrointestinal tract [11] nor
hydrolysed by a-amylases in the small intestine [5]. Besides the
endogenous solubilising components in the gastrointestinal tract,
i.e. bile salts and phosphorlipids, CDs should, hence, be capable of
dissolving more drug then stoichiometric amounts as the equili-
brium is dynamic and changes when the drug is absorbed. In
partly support of this hypothesis, Savolainen et al. [10] reported
similar bioavailability of phenytoin when dosed to dogs as either a
physical mixture with HPbCD or a preformed lyophilised complex
containing the same amount of CD. Savolainen and co-workers
[10], however, needed to dose 3 hard gelatine capsules size 000 to
achieve the desired dose demonstrating the previous mentioned
point on bulk volume of CDs. In contradiction to these results
several publications have reported a lower bioavailability from a
physical mixture than a premade lyophilised or spray dried
product [3,4,8,9]. To our knowledge no report can be found in
the literature where less CD have been administered than is need
to solubilise the compound in vitro.
Lu 35-138 (see Fig. 1); (S)-(þ)-[1-[2-(acetyl-2,3-dihydro-1H-
indol-3-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl]-6-chloro-1H-indole
Fig. 1. Chemical structure of Lu 35-138.
R. Holm et al. / Results in Pharma Sciences 1 (2011) 57–5958(Mw¼419.96 g/mol for the free base and 456.42 g/mol for the HCl
salt), is classiﬁed as an atypical antipsychotic on the basis of
antagonistic effects in the amphetamine rat model and other
antipsychotic in vivo models [6]. Non-published preformulation
studies of the compound demonstrated Lu 35-138 to be a weak
base with a pKa value of approximately 8 with a logD7.4 of 6.
Lu 35-138 was demonstrated to have a poor soluble in water,
5 mg/ml at pH 7.4 and 130 mg/ml at pH 6 and below, due to the
salt effect. The compound has a poor intrinsic dissolution rate on
0.016 and 0.0005 mg/cm2 min for the HCl salt and the free base,
respectively, and is deﬁned as a class II compound according
to the biopharmaceutical classiﬁcation system. Therefore, as
expected with these physical chemical properties, the bioavail-
ability of Lu 35-138 has been demonstrated to be less than 5% in
rats when dosed as a suspension (data not shown). Internal
investigations of a phase solubility study further showed
a complex of the AL type with a stability constant between Lu
35-138 and SBE7bCD on 4087 M1 at pH 3.5, i.e. for the ionised
compound relevant for the absorption in the gastrointestinal
tract, which indicates an effective solubilising effect of SBE7bCD.
The interaction between the two components was conﬁrmed by
1H-NMR. The purpose of this study is therefore to explore if Lu
35-138 from a tablet, of reasonable size, containing a physical
mixture with SBE7bCD could lead to plasma proﬁles similar to Lu
35-138 solubilised with SBE7bCD and/or to a spray dried complex.2. Experimental
Three formulations were evaluated in vivo; (i) a SBE7bCD
(CyDex, Lenexa, KS, USA) solution, (ii) a capsule formulation
containing a spray dried SBE7bCD solution, and (iii) a tablet
formulation containing a physical mixture of Lu 35-138 and
SBE7bCD. The drug:CD ratio used in the three formulations was
1:4.9, 1:23.3, and 1:2.4 for the solution, spray dried capsule, and
tablet, respectively.
The solution was prepared by dissolving 35-138 HCl (H.Lundbeck
A/S, Valby, Denmark), equal to 2 mg Lu 35-138 free base/ml, in a 5%
(w/v) SBE7bCD solution.
The spray dried product was produced by solubilising SBE7bCD
(300 g) and Lu 35-138-HCl (3.261 g) in 1 L of water at ambient
temperature. This solution was spray dried in a Mobile Minor
(GEA Niro A/S, Søborg, Denmark). The total dimensions of the
drying chamber were 0.84 m cylindrical height with a diameter of
0.80 m and a 601 conical base. Drying air ﬂow was 80 kg/h at a
chamber pressure of 5 mbar. A 1.5 mm two-ﬂuid nozzle, oper-
ating at a ﬂow of 4.2 kg air/h, was used to atomise the feed in
mixed-ﬂow mode. The inlet air temperature was maintained at
170 1C and the outlet air temperature was maintained on 100 1Cby regulation of the liquid feed-rate. A cyclone was used to collect
the powder. The obtained dry powder was ﬁlled into hard
gelatine capsules size 000 (Capsugel, Bornem, Belgium) and each
dog was dosed with 6 capsules containing 605 mg solid formula-
tion per capsule containing 5 mg Lu 35-138.
The tablet formulation was produced by manual blending of
50.5 g SBE7bCD and 4.076 g Lu 35-138 HCl. 1.13 g Ac–Di–Sol
(FMC, Cork, Ireland) was added as a disintegrant and 1.125 g
magnesium stearate (Peter Greve, Venlo, The Netherlands) as a
lubricant, and the mixture was blended further. The tablets were
compressed on an Erweka EK-0 tablet press (Erweka, Heusen-
stamm, Germany), using a 10-mm diameter, circular punch with
rounded faces. The tablet machine was adjusted to produce
tablets with a tablet weight on 450 mg and XRPD of the tablets
revealed no changes in the physical form. Each tablet contained
30 mg Lu 35-138 and 400 mg SBE7bCD and each dog was dosed
with one tablet.
The protocol used in the in vivo study was approved by the
Animal Welfare Committee appointed by the Danish Ministry of
Justice and all animal procedures were carried out in compliance
with EC Directive 86/609/EEC, the Danish law regulating experi-
ments with animals and the NIH guidelines on animal welfare.
Dogs were fasted for at least 15 h before administration of the
formulations, and water was available ad libitum during the study.
The animals were fed after the collection of the 9 h sample.
The SBE7bCD formulations were tested in four male beagle
dogs (5–7 years old, 14–16 kg) in a non-randomised cross-over
study, with a washout period of 7 days between each treatment.
All of the formulations contained 30 mg Lu 35-138. Blood samples
(2.0 ml) were obtained by individual vein puncture of vena
jugularis and collected into serum collection tubes. Samples were
collected at 5 min and 0.5, 1, 2, 3, 4, 6, 9, and 24 h after the drug
administration. Blood samples were allowed to clot for 60 min at
ambient temperature and then centrifuged at 1000 g for 10 min.
Serum aliquots were taken and frozen at 20 1C until analysis.
Serum concentrations of Lu 35-138 were determined by a
validated assay method using automated solid phase extraction
and subsequent LC–MS/MS analysis. On an ASPEC XL4 automated
solid phase extraction system (Gilson, Middleton, WI, USA) Oasis
HLB 1 cc 30 mg columns (Waters, Milford, MA, USA) were condi-
tioned with methanol and then puriﬁed water before sample
application. Columns were washed and eluted with methanol/
water (5:95) and 0.1% hydroquinone in methanol, respectively.
Samples were evaporated on a Turbo Vap LV evaporator (Zymark,
Hopkinton, MA, USA) and reconstituted in 100 mL of mobile phase
A. 10 mL of the reconstituted sample was injected on a LC–MS/MS-
system consisting of a HTS–PAL auto injector (CTC, Zwingen,
Switzerland), a HP1100 G1312A binary pump (Agilent, Palo
Alto, CA, USA), a HP1100 G1322A degasser (Agilent, Palo Alto,
CA, USA), a HP1100 G1316A column oven (Agilent, Palo Alto, CA,
USA) and a Quattro LC mass spectrometer (Micromass, Milford,
MA, USA). A chromatographic gradient separation was performed
with a run time of 18 min at a ﬂow rate of 1.0 mL/min at 40 1C on
a Symmetry C18, 1002.1 mm2 I.D., 3.5 mm column (Waters,
Milford, MA, USA) with an OPTI-guard C18 pre-column (Optimize
Technologies, Oregon City, OR, USA). Mobile phases were:
A (0–5 min and 9–18 min)¼50 mM ammonium acetate/acetoni-
trile (55:45), B (5–9 min)¼50 mM ammonium acetate/acetoni-
trile (20:80). The assay was linear between 0.4 ng/mL (LLOQ) and
40 ng/mL.
The pharmacokinetic parameters were obtained by standard
non-compartmental analysis using WinNonlin version 3.2 (Phar-
sight Corporation, Mountain View, CA, USA) and the statistical
analysis was performed by one-way analysis of variance (Sigma-
Stat for Windows version 3.0). The results were considered
signiﬁcant if Po0.05.
Fig. 2. Serum concentration versus time proﬁles after oral administration of
30 mg Lu 35-138 in three different SBE7bCD formulations. SBE7bCD-solution
(’), spray dried SBE7-bCD solution (m) and a SBE7bCD tablet of physical mixture
(K); (mean7S.E., n¼4).
Table 1
Pharmacokinetic parameters from non-compartmental analysis of the serum
concentration data after oral administration of 30 mg Lu 35-138 in three different
SBE7bCD formulations (mean7S.E., n¼4).
Treatment Tmax (h) cmax (nmol/L) AUC (nmol h/L)
Solution 2.7570.63 105720.8 11367250
Spray dried capsule 3.0070.71 85.5715.3 9977126
Physical mixture 3.0070.41 56.175.7 779779
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The serum concentration-time proﬁles after oral administra-
tion of Lu 35-138 to male beagle dogs in three different SBE7bCD
formulations are presented in Fig. 2 and the mean pharmacoki-
netic parameters in Table 1. Tmax was similar for the evaluated
formulations indicating that the in vivo absorption rate of Lu
35-138 was equal in the evaluated formulations.
No statistical differences were observed between the cmax or
AUC from the animals dosed with the SBE7bCD solution and the
spray dried system. A trend was, however, seen towards a slightly
lower absorption from the spray dried product when compared to
the solution indicating that the physical form has some effect on
the bioavailability of Lu 35-138. These observations are in accor-
dance with previous published results [3,4,8,9]. Another possible
explanation for this lower absorption from the spray dried product
could be the use of higher amounts of cyclodextrins. Previous
studies with strongly complexed compounds have shown that
extensive excess of CD may lower the bioavailability, presumably
due to limited release from the complex in the intestine [14].
The tablets containing a physical mixture of SBE7bCD and Lu
35-138 produced a mean cmax and AUC that tended to be lower
than both the SBE7bCD solution and the spray dried system,
though no statistical difference could be found. This indicates that
the pre-formation of the complex has a positive inﬂuence on the
bioavailability of Lu 35-138 and that the presence of crystalline
drug has a negative effect. This ﬁnding is contradictory to the
results with phenytoin published by Savolainen et al. [10], who
reported similar bioavailability, when dosed as a physical mixture
and as a lyophilised complex with HPbCD. One possible explana-
tion could be the intrinsic dissolution rate in water of Lu 35-138,
which is too poor even in the presence of SBE7bCD and endogenous
bile salts, to produce absorption at the same level as the preformed
complex. Further, in this study 750 mg and 3 g of SBE7bCD wasused in the solution and the spray dried product per dose
compared to the 400 mg in the tablet formulation. This difference
may also have induced a rate limiting step in the dissolution.
The tablet formulation leads to a relative bioavailability of
approximately 70%, when compared to the SBE7bCD solution. This
is, however, still higher than the bioavailability previously found for
Lu 35-138 when dosed in a hard gelatine capsule together with
30 mg of sodium lauryl sulphate (29% relative to the same reference
(unpublished data)). These observations indicate that preformed
complex with CDs is not a prerequisite and that the quantities of CD
in the formulation do not need to be sufﬁcient to solubilise all the
administered compound in order to obtain a decent enhancement in
the bioavailability of a low aqueous soluble drug. It should, however,
be stressed that the lack of statistical difference between the CD
solution and tablet is not a proof of the opposite hypothesis either,
i.e. that they are similar. A possible explanation for the minimal
difference between the solution and the tablet could be the dynamic
equilibrium in the gastrointestinal tract, as bCDs are not biologically
converted in the small intestine nor absorbed, where it can
solubilise more compound as this is continuously absorbed. The
tablet formulation, containing a physical mixture of drug and
SBE7bCD could therefore be an attractive formulation. The tablet
induced a relative high enhancement of the bioavailability of Lu 35-
138, it could be produced without expensive and difﬁcult pharma-
ceutical processing as lyophilization or spray drying and it had a
feasible size for commercialisation.
In summary, the oral bioavailability in beagle dogs of Lu 35-138
was not found statistically different when dosed as a SBE7bCD
solution, a spray dried solid complex, or a physical mixture of solid
Lu 35-138 and SBE7bCD. However, the in vivo data indicated a higher
oral bioavailability when dosed as a SBE7bCD solution, though at a
relative level where the simple and much cheaper tablet formulation
would still seem as the most cost effective formulation.
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